ccopy_reg
_reconstructor
p1
(ctethne.classes.paper
Paper
p2
c__builtin__
object
p3
NtRp4
(dp5
S'publisherCity'
p6
VROCKVILLE
p7
sS'reprintAddress'
p8
VLomonossoff, GP (reprint author), John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.
p9
sS'WC'
p10
VPlant Sciences
p11
sS'GA'
p12
V369UN
p13
sS'FX'
p14
(lp15
VThis work was supported in part by the European Union FP6 "PharmaPlanta"
p16
aVproject, by funding from a Marie Curie Early Stage Training Fellowship
p17
aV(grant no. MEST-CT-2004-504273 to F. S.), and by the Trustees of the
p18
aVJohn Innes Foundation.
p19
asS'abstract'
p20
VPlant-based overexpression of heterologous proteins has attracted much interest and development in recent years. To date, the most efficient vectors have been based on RNA virus-derived replicons. A system based on a disabled version of cowpea mosaic virus RNA-2 has been developed, which overcomes limitations on insert size and introduces biocontainment. This system involves positioning a gene of interest between the 5' leader sequence and 3' untranslated region (UTR) of RNA-2, thereby emulating a presumably stable mRNA for efficient translation. Thus far, the sequence of the 5' UTR has been preserved to maintain the ability of the modified RNA-2 to be replicated by RNA-1. However, high-level expression may be achieved in the absence of RNA-1-derived replication functions using Agrobacterium-mediated transient transformation. To investigate those features of the 5' UTR necessary for efficient expression, we have addressed the role of two AUG codons found within the 5' leader sequence upstream of the main initiation start site. Deletion of an in-frame start codon upstream of the main translation initiation site led to a massive increase in foreign protein accumulation. By 6 d postinfiltration, a number of unrelated proteins, including a full-size IgG and a self-assembling virus-like particle, were expressed to >10% and 20% of total extractable protein, respectively. Thus, this system provides an ideal vehicle for high-level expression that does not rely on viral replication of transcripts.
p21
sS'pageEnd'
p22
I1218
sS'date'
p23
I2008
sS'documentType'
p24
VArticle
p25
sS'subject'
p26
VPlant Sciences
p27
sS'isoSource'
p28
VPlant Physiol.
p29
sS'timesCited'
p30
(lp31
I74
aVZ9 78
p32
asS'funding'
p33
(lp34
(VEuropean Union FP6 "PharmaPlanta" project
Ntp35
a(VMarie Curie Early Stage Training Fellowship
VMEST-CT-2004-504273
tp36
a(VTrustees of the John Innes Foundation
Ntp37
asS'PT'
p38
VJ
sS'title'
p39
VExtremely High-Level And Rapid Transient Protein Production In Plants Without The Use Of Viral Replication
p40
sS'ISSN'
p41
(lp42
V0032-0889
p43
aVJ9 PLANT PHYSIOL
p44
asS'authors_full'
p45
(lp46
(VSAINSBURY
VFRANK
tp47
a(VLOMONOSSOFF
VGEORGE P
tp48
asS'PG'
p49
I7
sS'PD'
p50
VNOV
p51
sS'pageStart'
p52
I1212
sS'issue'
p53
I3
sS'RI'
p54
VSainsbury, Frank/I-2311-2013
p55
sS'journal'
p56
VPLANT PHYSIOLOGY
p57
sS'volume'
p58
V148
p59
sS'doi'
p60
V10.1104/pp.108.126284
p61
sS'emailAddress'
p62
Vgeorge.lomonossoff@bbsrc.ac.uk
p63
sS'authorAddress'
p64
V[Sainsbury, Frank; Lomonossoff, George P.] John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England.
p65
sS'publisherAddress'
p66
V15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
p67
sS'ER'
p68
V
sS'publisher'
p69
VAMER SOC PLANT BIOLOGISTS
p70
sS'authorKeywords'
p71
(lp72
VVIRUS-M-RNA
p73
aVEXPRESSION
p74
aVTRANSLATION
p75
aVANTIBODIES
p76
aVSYSTEMS
p77
aVVECTOR
p78
aVTRANSFORMATION
p79
aVCODONS
p80
aVHIV-1
p81
asS'language'
p82
VEnglish
p83
sS'wosid'
p84
VWOS:000260719500004
p85
sS'citationCount'
p86
I28
sS'authors_init'
p87
(lp88
(VSAINSBURY
VF
tp89
a(VLOMONOSSOFF
VG P
tp90
asS'citedReferences'
p91
(lp92
g1
(g2
g3
NtRp93
(dp94
g60
V10.1016/j.vaccine.2004.11.005
p95
sg56
VVACCINE
p96
sg58
VACCINE
p97
sg87
(lp98
(VAHLQUIST
VP
tp99
asg23
I2005
sg52
V1784
p100
sbag1
(g2
g3
NtRp101
(dp102
g60
V10.1107/S0907444906029805
p103
sg56
VACTA CRYSTALLOGR D
p104
sg58
V62
p105
sg87
(lp106
(VARICESCU
VA R
tp107
asg23
I2006
sg52
V1114
p108
sbag1
(g2
g3
NtRp109
(dp110
g60
V10.1089/aid.1994.10.359
p111
sg56
VAIDS RES HUM RETROV
p112
sg58
V10
p113
sg87
(lp114
(VBUCHACHER
VA
tp115
asg23
I1994
sg52
V359
p116
sbag1
(g2
g3
NtRp117
(dp118
g60
V10.1111/j.1467-7652.2005.00170.x
p119
sg56
VPLANT BIOTECHNOL J
p120
sg58
V4
sg87
(lp121
(VCANIZARES
VM C
tp122
asg23
I2006
sg52
VLANT
p123
sbag1
(g2
g3
NtRp124
(dp125
g60
V10.1016/j.virusres.2004.11.004
p126
sg56
VVIRUS RES
p127
sg58
VIRUS
p128
sg87
(lp129
(VCASTRO
VC
tp130
asg23
I2005
sg52
V141
p131
sbag1
(g2
g3
NtRp132
(dp133
g60
V10.1101/gad.12.15.2293
p134
sg56
VGENE DEV
p135
sg58
V12
p136
sg87
(lp137
(VGAMARNIK
VA V
tp138
asg23
I1998
sg52
V2293
p139
sbag1
(g2
g3
NtRp140
(dp141
g60
V10.1073/pnas.0606631103
p142
sg56
VP NATL ACAD SCI USA
p143
sg58
V103
p144
sg87
(lp145
(VGIRITCH
VA
tp146
asg23
I2006
sg52
V14701
p147
sbag1
(g2
g3
NtRp148
(dp149
g60
V10.1016/0042-6822(89)90133-5
p150
sg56
VVIROLOGY
p151
sg58
VIROLOGY
p152
sg87
(lp153
(VHOLNESS
VC L
tp154
asg23
I1989
sg52
V311
p155
sbag1
(g2
g3
NtRp156
(dp157
g60
V10.1104/pp.107.106377
p158
sg56
VPLANT PHYSIOL
p159
sg58
V145
p160
sg87
(lp161
(VLINDBO
VJ A
tp162
asg23
I2007
sg52
VLANT
p163
sbag1
(g2
g3
NtRp164
(dp165
g60
V10.1016/j.vaccine.2004.11.006
p166
sg56
VVACCINE
p167
sg58
VACCINE
p168
sg87
(lp169
(VLIU
VL
tp170
asg23
I2005
sg52
V1788
p171
sbag1
(g2
g3
NtRp172
(dp173
g60
V10.1038/nrg1177
p174
sg56
VNAT REV GENET
p175
sg58
V4
sg87
(lp176
(VMA
VJ K C
tp177
asg23
I2003
sg52
V794
p178
sbag1
(g2
g3
NtRp179
(dp180
g60
V10.1016/j.jviromet.2005.06.020
p181
sg56
VJ VIROL METHODS
p182
sg58
V131
p183
sg87
(lp184
(VMECHTCHERIAKOVA
VI A
tp185
asg23
I2006
sg52
V10
p186
sbag1
(g2
g3
NtRp187
(dp188
g60
V10.1128/MCB.20.23.8635-8642.2000
p189
sg56
VMOL CELL BIOL
p190
sg58
V20
p191
sg87
(lp192
(VMORRIS
VD R
tp193
asg23
I2000
sg52
V8635
p194
sbag1
(g2
g3
NtRp195
(dp196
g60
V10.1105/tpc.9.6.859
p197
sg56
VPLANT CELL
p198
sg58
V9
sg87
(lp199
(VPRUSS
VG
tp200
asg23
I1997
sg52
VLANT
p201
sbag1
(g2
g3
NtRp202
(dp203
g60
V10.1111/j.1467-7652.2007.00306.x
p204
sg56
VPLANT BIOTECHNOL J
p205
sg58
V6
sg87
(lp206
(VRADEMACHER
VT
tp207
asg23
I2008
sg52
VLANT
p208
sbag1
(g2
g3
NtRp209
(dp210
g60
V10.1007/s00299-003-0638-1
p211
sg56
VPLANT CELL REP
p212
sg58
V22
p213
sg87
(lp214
(VRICHARDS
VH A
tp215
asg23
I2003
sg52
VLANT
p216
sbag1
(g2
g3
NtRp217
(dp218
g60
V10.1006/viro.1993.1175
p219
sg56
VVIROLOGY
p220
sg58
VIROLOGY
p221
sg87
(lp222
(VROHLL
VJ B
tp223
asg23
I1993
sg52
V672
p224
sbag1
(g2
g3
NtRp225
(dp226
g60
V10.1016/j.virusres.2005.10.017
p227
sg56
VVIRUS RES
p228
sg58
VIRUS
p229
sg87
(lp230
(VRYABOVA
VL A
tp231
asg23
I2006
sg52
V52
p232
sbag1
(g2
g3
NtRp233
(dp234
g60
Nsg56
VVIRUS EXPRESSION VEC
p235
sg58
VIRUS
p236
sg87
(lp237
(VSAINSBURY
VF
tp238
asg23
I2007
sg52
V339
p239
sbag1
(g2
g3
NtRp240
(dp241
g60
Nsg56
VMETHODS BIOTECHNOLOG
p242
sg58
Nsg87
(lp243
(VSAINSBURY
VF
tp244
asg23
I2008
sg52
Nsbag1
(g2
g3
NtRp245
(dp246
g60
V10.1111/j.1467-7652.2007.00303.x
p247
sg56
VPLANT BIOTECHNOL J
p248
sg58
V6
sg87
(lp249
(VSAINSBURY
VF
tp250
asg23
I2008
sg52
VLANT
p251
sbag1
(g2
g3
NtRp252
(dp253
g60
V10.1016/j.tibtech.2003.10.002
p254
sg56
VTRENDS BIOTECHNOL
p255
sg58
V21
p256
sg87
(lp257
(VTWYMAN
VR M
tp258
asg23
I2003
sg52
V570
p259
sbag1
(g2
g3
NtRp260
(dp261
g60
V10.1006/viro.1993.1387
p262
sg56
VVIROLOGY
p263
sg58
VIROLOGY
p264
sg87
(lp265
(VVAN
VBOKHOVEN H
tp266
asg23
I1993
sg52
V377
p267
sbag1
(g2
g3
NtRp268
(dp269
g60
Nsg56
VTRANSGENIC RES
p270
sg58
V4
sg87
(lp271
(VVANENGELEN
VF A
tp272
asg23
I1995
sg52
V288
p273
sbag1
(g2
g3
NtRp274
(dp275
g60
V10.1046/j.1365-313X.2003.01676.x
p276
sg56
VPLANT J
p277
sg58
V33
p278
sg87
(lp279
(VVOINNET
VO
tp280
asg23
I2003
sg52
VLANT
p281
sbag1
(g2
g3
NtRp282
(dp283
g60
Nsg56
VJ VIROL
p284
sg58
V67
p285
sg87
(lp286
(VWELLINK
VJ
tp287
asg23
I1993
sg52
V3660
p288
sbag1
(g2
g3
NtRp289
(dp290
g60
V10.1016/0300-9084(93)90105-2
p291
sg56
VBIOCHIMIE
p292
sg58
V75
p293
sg87
(lp294
(VWELLINK
VJ
tp295
asg23
I1993
sg52
V741
p296
sbag1
(g2
g3
NtRp297
(dp298
g60
V10.1016/j.biotec.2006.07.012
p299
sg56
VJ BIOTECHNOL
p300
sg58
V127
p301
sg87
(lp302
(VYIN
VJ C
tp303
asg23
I2007
sg52
V335
p304
sbasb.